Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Cardiovascular Outcomes and All-Cause Mortality in Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease (Overlap Syndrome).

Kendzerska T, Leung RS, Aaron SD, Ayas N, Sandoz JS, Gershon AS; Canadian Respiratory Research Network.

Ann Am Thorac Soc. 2018 Oct 29. doi: 10.1513/AnnalsATS.201802-136OC. [Epub ahead of print]

PMID:
30372124
2.

Sleep Apnea Increases the Risk of New Hospitalized Atrial Fibrillation: A Historical Cohort Study.

Kendzerska T, Gershon AS, Atzema C, Dorian P, Mangat I, Hawker G, Leung RS.

Chest. 2018 Sep 19. pii: S0012-3692(18)32437-1. doi: 10.1016/j.chest.2018.08.1075. [Epub ahead of print]

PMID:
30243978
3.

Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease.

Diab N, Gershon AS, Sin DD, Tan WC, Bourbeau J, Boulet LP, Aaron SD.

Am J Respir Crit Care Med. 2018 Nov 1;198(9):1130-1139. doi: 10.1164/rccm.201804-0621CI.

PMID:
29979608
4.

Serotonergic antidepressant use and morbidity and mortality among older adults with COPD.

Vozoris NT, Wang X, Austin PC, Stephenson AL, O'Donnell DE, Gershon AS, Gill SS, Rochon PA.

Eur Respir J. 2018 Jul 27;52(1). pii: 1800475. doi: 10.1183/13993003.00475-2018. Print 2018 Jul.

PMID:
29946006
5.

Feasibility of Using a Smartwatch to Intensively Monitor Patients With Chronic Obstructive Pulmonary Disease: Prospective Cohort Study.

Wu R, Liaqat D, de Lara E, Son T, Rudzicz F, Alshaer H, Abed-Esfahani P, Gershon AS.

JMIR Mhealth Uhealth. 2018 Jun 14;6(6):e10046. doi: 10.2196/10046.

6.

End-of-Life Strategies among Patients with Advanced Chronic Obstructive Pulmonary Disease.

Gershon AS, Maclagan LC, Luo J, To T, Kendzerska T, Stanbrook MB, Bourbeau J, Etches J, Aaron SD.

Am J Respir Crit Care Med. 2018 Dec 1;198(11):1389-1396. doi: 10.1164/rccm.201803-0592OC.

PMID:
29889548
7.

Can Patients With COPD Assimilate Disease-Specific Information During an Acute Exacerbation?: Results of a Pilot Randomized Controlled Trial.

Janaudis-Ferreira T, Carr SJ, Harrison SL, Gershon AS, Milner SC, Carr S, Fishbein D, Goldstein R.

Chest. 2018 Sep;154(3):588-596. doi: 10.1016/j.chest.2018.05.028. Epub 2018 Jun 4.

PMID:
29879395
8.

Underdiagnosis and Overdiagnosis of Asthma.

Aaron SD, Boulet LP, Reddel HK, Gershon AS.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):1012-1020. doi: 10.1164/rccm.201804-0682CI.

PMID:
29756989
9.

Clinical Knowledge from Observational Studies. Everything You Wanted to Know but Were Afraid to Ask.

Gershon AS, Jafarzadeh SR, Wilson KC, Walkey AJ.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):859-867. doi: 10.1164/rccm.201801-0118PP. No abstract available.

PMID:
29733678
10.

Reply to Goulden et al.: Risk of Bias in Study of Varenicline and Cardiovascular Outcomes.

Gershon AS, Campitelli MA, Hawken S, Sproule BA, Selby P.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):691-692. doi: 10.1164/rccm.201804-0639LE. No abstract available.

PMID:
29708391
11.

Asthma health services utilisation before, during and after pregnancy: a population-based cohort study.

To T, Feldman LY, Zhu J, Gershon AS.

Eur Respir J. 2018 Apr 19;51(4). pii: 1800209. doi: 10.1183/13993003.00209-2018. Print 2018 Apr.

PMID:
29519927
12.

Health Services Burden of Undiagnosed and Overdiagnosed COPD.

Gershon AS, Thiruchelvam D, Chapman KR, Aaron SD, Stanbrook MB, Bourbeau J, Tan W, To T; Canadian Respiratory Research Network.

Chest. 2018 Jun;153(6):1336-1346. doi: 10.1016/j.chest.2018.01.038. Epub 2018 Feb 6.

PMID:
29425675
13.

Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation.

Gershon AS, Campitelli MA, Hawken S, Victor C, Sproule BA, Kurdyak P, Selby P.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):913-922. doi: 10.1164/rccm.201706-1204OC.

PMID:
29260881
14.

Home Mechanical Ventilation: A 12-Year Population-Based Retrospective Cohort Study.

Povitz M, Rose L, Shariff SZ, Leonard S, Welk B, Jenkyn KB, Leasa DJ, Gershon AS.

Respir Care. 2018 Apr;63(4):380-387. doi: 10.4187/respcare.05689. Epub 2017 Dec 5.

PMID:
29208755
15.

Risk Trajectories of Readmission and Death in the First Year after Hospitalization for Chronic Obstructive Pulmonary Disease.

Lindenauer PK, Dharmarajan K, Qin L, Lin Z, Gershon AS, Krumholz HM.

Am J Respir Crit Care Med. 2018 Apr 15;197(8):1009-1017. doi: 10.1164/rccm.201709-1852OC.

PMID:
29206052
16.

Incident diuretic drug use and adverse respiratory events among older adults with chronic obstructive pulmonary disease.

Vozoris NT, Wang X, Austin PC, O'Donnell DE, Aaron SD, To TM, Gershon AS.

Br J Clin Pharmacol. 2018 Mar;84(3):579-589. doi: 10.1111/bcp.13465. Epub 2017 Dec 6.

PMID:
29139564
17.

Concomitant pulmonologist and primary care for chronic obstructive pulmonary disease: a population study.

Gershon AS, Macdonald EM, Luo J, Austin PC, Gupta S, Sivjee K, Upshur R, Aaron SD.

Fam Pract. 2017 Nov 16;34(6):708-716. doi: 10.1093/fampra/cmx058.

PMID:
28985364
18.

The risk of mycobacterial infections associated with inhaled corticosteroid use.

Brode SK, Campitelli MA, Kwong JC, Lu H, Marchand-Austin A, Gershon AS, Jamieson FB, Marras TK.

Eur Respir J. 2017 Sep 20;50(3). pii: 1700037. doi: 10.1183/13993003.00037-2017. Print 2017 Sep.

PMID:
28931659
19.

Obstructive sleep apnoea is not a risk factor for incident hospitalised depression: a historical cohort study.

Kendzerska T, Gershon AS, Hawker GA, Tomlinson GA, Leung RS.

Eur Respir J. 2017 Jun 1;49(6). pii: 1601361. doi: 10.1183/13993003.01361-2016. Print 2017 Jun.

20.
21.

The Cardiovascular Health in Ambulatory Care Research Team performance indicators for the primary prevention of cardiovascular disease: a modified Delphi panel study.

Tu JV, Maclagan LC, Ko DT, Atzema CL, Booth GL, Johnston S, Tu K, Lee DS, Bierman A, Hall R, Bhatia RS, Gershon AS, Tobe SW, Sanmartin C, Liu P, Chu A; CANHEART Primary Prevention Indicator Expert Panel.

CMAJ Open. 2017 Apr 25;5(2):E315-E321. doi: 10.9778/cmajo.20160139.

22.

Concurrent physician-diagnosed asthma and chronic obstructive pulmonary disease: A population study of prevalence, incidence and mortality.

Kendzerska T, Sadatsafavi M, Aaron SD, To TM, Lougheed MD, FitzGerald JM, Gershon AS; Canadian Respiratory Research Network.

PLoS One. 2017 Mar 16;12(3):e0173830. doi: 10.1371/journal.pone.0173830. eCollection 2017.

23.

Pulmonary Nontuberculous Mycobacteria-Associated Deaths, Ontario, Canada, 2001-2013.

Marras TK, Campitelli MA, Lu H, Chung H, Brode SK, Marchand-Austin A, Winthrop KL, Gershon AS, Kwong JC, Jamieson FB.

Emerg Infect Dis. 2017 Mar;23(3):468-476. doi: 10.3201/eid2303.161927.

24.

Inhaled Long-acting Anticholinergics and Urinary Tract Infection in Individuals with COPD.

Gershon AS, Newman AM, Fischer HD, Austin PC, Daneman N, Bell CM, Stephenson AL, Gill SS, Vozoris NT, Rochon PA.

COPD. 2017 Feb;14(1):105-112. doi: 10.1080/15412555.2016.1202912. Epub 2016 Oct 12.

PMID:
27732117
25.

Influence of country-level differences on COPD prevalence.

Aaron SD, Gershon AS, Gao Y, Yang J, Whitmore GA.

Int J Chron Obstruct Pulmon Dis. 2016 Sep 19;11:2305-2313. eCollection 2016.

26.
27.

The impact of a history of asthma on long-term outcomes of people with newly diagnosed chronic obstructive pulmonary disease: A population study.

Kendzerska T, To TM, Aaron SD, Lougheed MD, Sadatsafavi M, FitzGerald JM, Gershon AS; Canadian Respiratory Research Network.

J Allergy Clin Immunol. 2017 Mar;139(3):835-843. doi: 10.1016/j.jaci.2016.06.026. Epub 2016 Sep 15.

PMID:
27641119
28.

Factors associated with undiagnosed and overdiagnosed COPD.

Gershon AS, Hwee J, Chapman KR, Aaron SD, O'Donnell DE, Stanbrook MB, Bourbeau J, Tan W, Su J, Victor JC, To T.

Eur Respir J. 2016 Aug;48(2):561-4. doi: 10.1183/13993003.00458-2016. Epub 2016 Jun 23. No abstract available.

29.

Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease.

Marras TK, Campitelli MA, Kwong JC, Lu H, Brode SK, Marchand-Austin A, Gershon AS, Jamieson FB.

Eur Respir J. 2016 Sep;48(3):928-31. doi: 10.1183/13993003.00033-2016. Epub 2016 Jun 10. No abstract available.

30.

The Annual September Peak in Asthma Exacerbation Rates. Still a Reality?

Larsen K, Zhu J, Feldman LY, Simatovic J, Dell S, Gershon AS, To T.

Ann Am Thorac Soc. 2016 Feb;13(2):231-9. doi: 10.1513/AnnalsATS.201508-545OC.

PMID:
26636481
31.

The Effect of Patient Neighborhood Income Level on the Purchase of Continuous Positive Airway Pressure Treatment among Patients with Sleep Apnea.

Kendzerska T, Gershon AS, Tomlinson G, Leung RS.

Ann Am Thorac Soc. 2016 Jan;13(1):93-100. doi: 10.1513/AnnalsATS.201505-294OC.

PMID:
26473580
32.

Pulmonary Rehabilitation in Ontario: A Cross-Sectional Survey.

Bowen JM, Campbell K, Sutherland S, Bartlett A, Brooks D, Qureshi R, Goldstein R, Gershon AS, Prevost S, Samis L, Kaplan AG, Hopkins RB, MacDougald C, Nunes E, O'Reilly DJ, Goeree R.

Ont Health Technol Assess Ser. 2015 Mar 1;15(8):1-67. eCollection 2015.

33.

Health risk of air pollution on people living with major chronic diseases: a Canadian population-based study.

To T, Feldman L, Simatovic J, Gershon AS, Dell S, Su J, Foty R, Licskai C.

BMJ Open. 2015 Sep 2;5(9):e009075. doi: 10.1136/bmjopen-2015-009075.

34.

Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study.

Vozoris NT, Wang X, Fischer HD, Gershon AS, Bell CM, Gill SS, O'Donnell DE, Austin PC, Stephenson AL, Rochon PA.

Br J Clin Pharmacol. 2016 Jan;81(1):161-70. doi: 10.1111/bcp.12762. Epub 2015 Oct 2.

35.

Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996-2012.

Albaum JM, Lévesque LE, Gershon AS, Liu G, Cadarette SM.

Osteoporos Int. 2015 Dec;26(12):2845-52. doi: 10.1007/s00198-015-3200-4. Epub 2015 Jul 3.

PMID:
26138581
36.

Trends in Pulmonary Function Testing Before Noncardiothoracic Surgery.

Sun LY, Gershon AS, Ko DT, Thilen SR, Yun L, Beattie WS, Wijeysundera DN.

JAMA Intern Med. 2015 Aug;175(8):1410-2. doi: 10.1001/jamainternmed.2015.2087. No abstract available.

PMID:
26053615
37.

Quality of asthma care under different primary care models in Canada: a population-based study.

To T, Guan J, Zhu J, Lougheed MD, Kaplan A, Tamari I, Stanbrook MB, Simatovic J, Feldman L, Gershon AS.

BMC Fam Pract. 2015 Feb 14;16:19. doi: 10.1186/s12875-015-0232-y.

38.

The Cardiovascular Health in Ambulatory Care Research Team (CANHEART): using big data to measure and improve cardiovascular health and healthcare services.

Tu JV, Chu A, Donovan LR, Ko DT, Booth GL, Tu K, Maclagan LC, Guo H, Austin PC, Hogg W, Kapral MK, Wijeysundera HC, Atzema CL, Gershon AS, Alter DA, Lee DS, Jackevicius CA, Bhatia RS, Udell JA, Rezai MR, Stukel TA.

Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):204-12. doi: 10.1161/CIRCOUTCOMES.114.001416. Epub 2015 Feb 3.

PMID:
25648464
39.

Long-acting β-agonists with vs without inhaled corticosteroids for COPD--reply.

Gershon AS, Campitelli MA, Stanbrook MB.

JAMA. 2015 Jan 20;313(3):305-6. doi: 10.1001/jama.2014.16479. No abstract available.

PMID:
25603005
40.

Osteoporosis management among chronic glucocorticoid users: a systematic review.

Albaum JM, Youn S, Levesque LE, Gershon AS, Cadarette SM.

J Popul Ther Clin Pharmacol. 2014;21(3):e486-504. Epub 2014 Nov 24. Review.

PMID:
25527817
41.

Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease.

Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R, Stephenson AL, Stukel TA.

JAMA. 2014 Sep 17;312(11):1114-21. doi: 10.1001/jama.2014.11432.

PMID:
25226477
42.

Trends in socioeconomic status-related differences in mortality among people with chronic obstructive pulmonary disease.

Gershon AS, Hwee J, Victor JC, Wilton AS, To T.

Ann Am Thorac Soc. 2014 Oct;11(8):1195-202. doi: 10.1513/AnnalsATS.201403-094OC.

PMID:
25166428
43.

Quantifying comorbidity in individuals with COPD: a population study.

Gershon AS, Mecredy GC, Guan J, Victor JC, Goldstein R, To T.

Eur Respir J. 2015 Jan;45(1):51-9. doi: 10.1183/09031936.00061414. Epub 2014 Aug 19.

44.

Obstructive sleep apnea and the prevalence and incidence of cancer.

Kendzerska T, Leung RS, Hawker G, Tomlinson G, Gershon AS.

CMAJ. 2014 Sep 16;186(13):985-92. doi: 10.1503/cmaj.140238. Epub 2014 Aug 5.

45.

Obstructive sleep apnea and incident diabetes. A historical cohort study.

Kendzerska T, Gershon AS, Hawker G, Tomlinson G, Leung RS.

Am J Respir Crit Care Med. 2014 Jul 15;190(2):218-25. doi: 10.1164/rccm.201312-2209OC.

PMID:
24897551
46.

Asthma and chronic obstructive pulmonary disease (COPD) prevalence and health services use in Ontario Métis: a population-based cohort study.

Gershon AS, Khan S, Klein-Geltink J, Wilton D, To T, Crighton EJ, Pigeau L, Macquarrie J, Allard Y, Russell SJ, Henry DA.

PLoS One. 2014 Apr 23;9(4):e95899. doi: 10.1371/journal.pone.0095899. eCollection 2014.

47.

Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD.

Vozoris NT, Fischer HD, Wang X, Stephenson AL, Gershon AS, Gruneir A, Austin PC, Anderson GM, Bell CM, Gill SS, Rochon PA.

Eur Respir J. 2014 Aug;44(2):332-40. doi: 10.1183/09031936.00008014. Epub 2014 Apr 17.

48.

Obstructive sleep apnea and risk of cardiovascular events and all-cause mortality: a decade-long historical cohort study.

Kendzerska T, Gershon AS, Hawker G, Leung RS, Tomlinson G.

PLoS Med. 2014 Feb 4;11(2):e1001599. doi: 10.1371/journal.pmed.1001599. eCollection 2014 Feb.

49.

Demographic characteristics and healthcare use of centenarians: a population-based cohort study.

Rochon PA, Gruneir A, Wu W, Gill SS, Bronskill SE, Seitz DP, Bell CM, Fischer HD, Stephenson AL, Wang X, Gershon AS, Anderson GM.

J Am Geriatr Soc. 2014 Jan;62(1):86-93. doi: 10.1111/jgs.12613. Epub 2014 Jan 2.

PMID:
24383610
50.

Patient and physician factors associated with pulmonary function testing for COPD: a population study.

Gershon AS, Hwee J, Croxford R, Aaron SD, To T.

Chest. 2014 Feb;145(2):272-281. doi: 10.1378/chest.13-0790.

PMID:
24008897

Supplemental Content

Loading ...
Support Center